From Wikipedia, the free encyclopedia
Jump to: navigation, search

CNV1014802 is a novel analgesic under development by Convergence Pharmaceuticals for the treatment of lumbosacral radiculopathy (sciatica) and trigeminal neuralgia (TGN).[1][2][3] It acts as a selective, small-molecule, state-dependent Nav1.7 voltage-gated sodium channel blocker.[1][2] The molecule is believed to be (5R)-5-(4-{[2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide as based on the FDA Orphan Drug Designation granted 07-24-13 for the treatment of trigeminal neuralgia.[4] In June 2014, Convergence presented positive results for a phase II clinical study of CNV1014802 in the treatment of TGN, including findings that the drug had an excellent efficacy and safety profile and was well-tolerated.[5][non-primary source needed]

The purported structure of the drug "CNV1014802"

See also[edit]


  1. ^ a b Convergence Pharmaceuticals. "CNV1014802 - Convergence Pharmaceuticals". 
  2. ^ a b Stephen McMahon; Martin Koltzenburg; Irene Tracey; Dennis C. Turk (1 March 2013). Wall & Melzack's Textbook of Pain: Expert Consult - Online. Elsevier Health Sciences. p. 508. ISBN 0-7020-5374-0. 
  3. ^ Bagal, Sharan K.; Chapman, Mark L.; Marron, Brian E.; Prime, Rebecca; Ian Storer, R.; Swain, Nigel A. (2014). "Recent progress in sodium channel modulators for pain". Bioorganic & Medicinal Chemistry Letters 24 (16): 3690–9. doi:10.1016/j.bmcl.2014.06.038. ISSN 0960-894X. PMID 25060923. 
  4. ^
  5. ^ MarketWatch (2014). "Convergence Pharmaceuticals' Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy and Safety in Ground-breaking Phase II Trigeminal Neuralgia Study".